CEDRUS’s Akebia Therapeutics AKBA Stock Holding History

CEDRUS’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$18.1K	Hold	13,700	–	–	0.01%	182
2024 Q2	$14K	Buy	+13,700	New	+$16.9K	0.01%	154

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CEDRUS's AKBA Position: Q3 2024 in Review

CEDRUS held its Akebia Therapeutics (AKBA) position steady in Q3 2024 at 13,700 shares worth $18.1K. The position accounts for 0.01% of the portfolio, ranked #182.

CEDRUS first reported a position in AKBA in Q2 2024 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

CEDRUS held 13,700 shares of Akebia Therapeutics worth $18.1K as of Q3 2024.
CEDRUS left its Akebia Therapeutics share count unchanged in Q3 2024.
Akebia Therapeutics made up 0.01% of CEDRUS's portfolio in Q3 2024, its #182 holding.
CEDRUS first reported a position in Akebia Therapeutics in Q2 2024 and has held it in 2 quarters since.
114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on CEDRUS's 13F filing for Q3 2024, filed 18 Oct 2024.